Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study)
Unknown statusPhase 2NCT00377468
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to determine whether application of low dose Delta9-Tetrahydrocannabinol can prevent the development of chronic pain in patients with acute CRPS.
Study details
- Official title
- Low Dose Administration of Delta9-Tetrahydrocannabinol for the Prevention of Hyperalgesia and Chronic Pain in Patients With Acute Complex Regional Pain Syndrome (CRPS) of the Upper Limb
- Conditions
- Interventions
- Drug: Delta9-Tetrahydrocannabinol
- Sponsor
- Ludwig-Maximilians - University of Munich
- Collaborators
- German Federal Ministry of Education and Research; German Research Network on Neuropathic Pain
- Start date
- 2006-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Germany
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with clinical diagnosis of acute CRPS (time from inciting event less than 16 weeks) of the upper extremity * No risk of dependency in a psychological assessment Exclusion Criteria: * History of alcohol or drug abuse * Cardiac arrhythmias * Acute or chronic renal failure * ASA physical status classification III or higher * Psychiatric disorders * Pregnancy and breast feeding
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00377468